Table 4 Comparative analysis of treatment efficiency of different HCV genotypes (GTs) from 2017 to 2021 by Fisher’s exact test

Treatment Regime

Genotypes

Number of patients who have achieved SVR₁₂ against DAAs between Jan 2017 and Dec 2018

(n = 64/66; 96.97%)

Number of patients who have achieved SVR₁₂ against DAAs between Jan 2019 and Dec 2021

(n = 71/75; 94.67%)

p-value

SOF/DCV

SVR₁₂ achieved

Non-responder

SVR₁₂ achieved

Non-responder

Gen-1c

100%

(10/10)

0%

(0/10)

90.70%

(39/43)

9.30%

(4/43)

0.55

Gen-1a

100%

(2/2)

0%

(0/2)

100%

(7/7)

0%

(0/7)

-

Gen-4a

100%

(4/4)

0%

(0/4)

100%

(2/2)

0%

(0/2)

-

Gen-3a

100%

(4/4)

0%

(0/4)

100%

(4/4)

0%

(4/4)

-

Gen-1b

-

-

100%

(2/2)

0%

(0/2)

-

Gen-3b

100%

(2/2)

0%

(0/2)

100%

(2/2)

0%

(0/2)

-

SOF/LDV

Gen-1c

94.73%

(36/38)

5.26%

(2/38)

-

-

-

Gen-1a

100%

(4/4)

0%

(0/4)

-

-

-

Gen-4a

-

-

-

-

-

Gen-3a

-

-

-

-

-

Gen-1b

100%

(2/2)

0%

(0/2)

-

-

-

Gen-3b

-

-

-

-

-

SOF/VEL

Gen-1c

-

-

100%

(12/12)

0%

(0/12)

-

Gen-1a

-

-

-

-

-

Gen-4a

-

-

100%

(3/3)

0%

(0/3)

-

Gen-3a

-

-

-

-

-

Gen-1b

-

-

-

-

-

Gen-3b

-

-

-

-

-